Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.6 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Spirox, Inc. Announces Closing of $18.5MM Series B Financing

April 20, 2015
MENLO PARK, Calif., April 20, 2015 /PRNewswire/ -- Spirox Inc., a privately held medical device company, announced today the closing of an $18.5 million Series B round of financing led…

TransEnterix Announces Completion of GLP Studies

April 16, 2015
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, today…

Cynapsus Therapeutics Announces CAD$21 Million Private Placement

March 31, 2015
TORONTO – Cynapsus Therapeutics Inc. (TSX: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson’s disease, today announced the completion of a private…